Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : Melphalan is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
November 04, 2019
Lead Product(s) : Pamiparib
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : BeOne Medicines
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pamiparib is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 12, 2017
Lead Product(s) : Pamiparib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : BeOne Medicines
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tislelizumab
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : BeOne Medicines
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tislelizumab is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
January 21, 2016
Lead Product(s) : Tislelizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : BeOne Medicines
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olaparib
Therapeutic Area : Oncology
Study Phase : Phase III
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Olaparib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Ovarian Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 19, 2015
Lead Product(s) : Olaparib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Recipient : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
